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Membranoproliferative glomerulonephritis (MPGN)
associated with type II cryoglobulinemia is the predominant
type of hepatitis C virus (HCV)-related glomerulonephritis.
The blockade of the renin–angiotensin system, as well as a
combined anti-HCV therapy that associates standard or
pegylated a-interferon with ribavirin, are mandatory in all
patients experiencing an HCV-related glomerulonephritis. In
patients with nephrotic-range proteinuria and/or progressive
renal failure, immunosuppressive therapy is necessary.
Rituximab, the monoclonal anti-CD20 antibody that
selectively targets the B cells, seems to be as least as
efficient as cyclophosphamide. Because it is also better
tolerated, it should be preferred to cyclophosphamide.
During the acute phase, plasmapheresis and steroid pulses
can be used. However, future prospective, controlled,
and randomized studies are still required to establish
evidence-based guidelines to treat HCV-related
glomerulopathies.
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Hepatitis C virus (HCV) infection leads to chronic liver
disease, but also to extra-hepatic manifestations.1 These
include mixed cryoglobulinemia, lymphoproliferative disor-
ders and renal disease. HCV infection has been reported in
association with distinct histological patterns of glomerulo-
nephritis in native kidneys. Membranoproliferative glomerulo-
nephritis (MPGN) associated with type II cryoglobulinemia is
the predominant type of HCV-related glomerulonephritis.2
Less common glomerulonephritis have also been reported in
HCV-infected patients. Of these, MPGN without cryoglobulin-
emia,3 membranous glomerulonephritis,3 focal segmental
glomerular sclerosis,4 proliferative glomerulonephritis,3,5 renal
thrombotic microangiopathy associated with anticardiolipin
antibodies,6 and fibrillary and immunotactoid glomerulo-
pathies.7 In this mini-review, we focus on the treatment of
HCV-related cryoglobulinemic glomerulonephritis.
CRYOGLOBULINEMIC MPGN
More than 80% of patients with mixed cryoglobulinemia
are infected by HCV, and cryoglobulinemia is found in all
patients with HCV-related MPGN.2 Cryoglobulins are
immunoglobulins (Igs) that precipitate at cold temperature.
HCV-associated cryoglobulinemic glomerulonephritis seems
to be related to the deposition in the glomerulus of immune
complexes made by the HCV antigen, anti-HCVIg G
antibodies, and a rheumatoid factor, which is an IgM kappa.
Clinically, patients present with proteinuria and microscopic
hematuria. Nephrotic syndrome and acute nephritic
syndrome, with rapid deterioration of renal function, are
observed in, respectively, 20 and 25% of patients.2,8 Fifty
percent of patients have moderate renal insufficiency,2 and
hypertension is present in 80% of patients.8 HCV-related
cryoglobulinemic renal disease is often associated with
extra-renal manifestations. The most frequently observed
are purpura, arthralgia and peripheral neuropathy.9
Laboratory parameters reveal the presence of circulating
cryoglobulins, which are most commonly type II cryoglo-
bulins in which the rheumatoid factor is an IgM kappa. The
complement components, C4 and C1q, are usually low.
Serum C3 level is also moderately decreased. Serum anti-
HCV antibodies and HCV RNA are detected in both the
serum and the cryoprecipitate. HCV RNA concentrates in
cryoprecipitate (1000-fold higher than in the serum).
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Histological examination of kidney biopsies usually reveals
the presence of glomerular infiltration by activated macro-
phages. The glomerular basement membrane shows double
contours, which are caused by the interposition of monocytes
between the basement membrane and the endothelium.
Immunofluorescence exhibits subendothelial deposits of
IgM, IgG, and the complement components. On electron
microscopy, large subendothelial deposits are present.
Vasculitis of small renal arteries is present in 30% of cases.
In most cases, the renal prognosis is good;8 however, renal
disease remain the first cause of morbid-mortality in mixed
cryoglobulinemia.8
TREATMENT OF HCV-RELATED GLOMERULONEPHRITIS
Symptomatic therapy
Blood pressure control, diuretics, the blockade of the
renin–angiotensin system using either angiotensin-converting
enzyme inhibitor alone or combined with an angiotensin
receptor antagonist, as well as the treatment of hyperlipide-
mia, are of proven benefit.10
Anti-HCV therapy
Beacause a link has been established between HCV infection
and the occurrence of cryoglobulinemic MPGN, an anti-viral
therapy has been used in HCV-positive patients presenting
with a glomerulonephritis in order to achieve clearance
of HCV from the serum and, consequently, to have a bene-
ficial effect on renal injury. In the early 1990s, standard
a-interferon (a-IFN) has been used alone. Unfortunately, the
results were disappointing. In 15 patients who had a
complete clearance of HCV RNA after a-IFN therapy,
Misiani et al.11 reported an improvement in renal function.
In contrast, there was no effect on proteinuria. All patients
relapsed after a-IFN therapy was stopped. Later, Johnson
et al.5 reported the results of a prospective uncontrolled study
where 14 patients experiencing an HCV-related glomerulo-
nephritis were treated with a-IFN for 6–12 months. Overall,
proteinuria significantly decreased, whereas renal function
remained stable. In 11 patients, sera were tested for HCV
RNA while on this therapy. Patients who became cleared of
HCV RNA (n¼ 6) had a better outcome compared to those
who remained HCV RNA positive (n¼ 5). However,
virological and renal relapses were observed after completing
the therapy. In this study, the use of oral prednisone, in
addition to a-IFN, in five patients had no effect on renal
function. In contrast, steroid pulses had a beneficial effect in
two patients. Finally, the use of cytotoxic agents, with or
without plasma exchange, was associated with a high rate of
death and a flare up in HCV viremia.5
During the last few years, a combined therapy of a-IFN,
especially pegylated IFN, with ribavirin has become the
golden standard of HCV treatment because it has been found
to be more effective than a-IFN alone. This has prompted
physicians to treat HCV-related glomerulonephritis with this
combination. However, published case reports and uncon-
trolled studies have only included small numbers of patients
so far. In a prospective uncontrolled study, Sabry et al.12
treated 20 patients presenting with MPGN (n¼ 17),
membranous glomerulonephritis (n¼ 2) and mesangiopro-
liferative glomerulonephritis (n¼ 1) with a-IFN and either
with or without ribavirin. All patients were given a-IFN
3 million units (MU) three times weekly. In cases of
persistent HCV RNA at 3 months, ribavirin was added at
the daily dose of 15 mg/kg. The treatment was continued for
12 months. Four out of the 20 patients became HCV RNA
negative within the first 3 months and, consequently, did not
receive ribavirin therapy. Only one out of the 16 remaining
patients, who additionally received ribavirin, became cleared
of HCV RNA within the serum. Seven patients underwent a
ribavirin dose reduction because of adverse events, mainly
hemolytic anemia. Overall, both HCV RNA concentration
and proteinuria decreased significantly. Serum albumin
level, as well as both C3 and C4 levels, increased significantly.
Renal function remained stable. In this study by Sabry et al.,
no data are provided regarding the outcome of renal
disease after cessation of anti-HCV therapy. In a retrospective
study, Bruchfeld et al.13 report on their first treatment
with concentration-controlled ribavirin plus a-IFN therapy
in HCV-related glomerular disease. The intended trough
ribavirin plasma concentration was 10–15 mmol/l. Four
patients received standard a-IFN, two received pegylated
a-IFN and ribavirin, and one patient received ribavirin
monotherapy because of bad tolerance of a-IFN. Five of the
patients had a sustained virological response 6–32 months
after anti-viral therapy was stopped. One patient relapsed
3 months after completing therapy, whereas one patient who
was on ribavirin monotherapy did not had a virological
response. Serum albumin level normalized in all patients.
Proteinuria decreased in all patients. Glomerular filtration
rate improved in three patients and remained stable in four
other patients. Despite monitoring ribavirin plasma concen-
tration, the main side effect observed was ribavirin-induced
hemolytic anemia, which required ribavirin dose reduction,
low-dose iron and systematic erythropoı¨etin support. Later,
Rossi et al.14 reported a decrease in proteinuria and an
improvement in renal histology.
More recently, we treated 18 patients who had HCV-
related cryoglobulinemic MPGN with a combined therapy of
standard or pegylated IFN and ribavirin.15 After a sympto-
matic treatment of nephrotic-range proteinuria by furose-
mide, with or without angiotensin-converting enzyme
inhibitors, and with or without plasma exchange that
was or was not associated with steroids, 18 patients received
anti-HCV therapy, whereas seven other patients did not
receive any anti-viral therapy. Fourteen out of the 18 were
treated with standard a-IFN 3 MU three times weekly
plus ribavirin at 600 to 1000 mg/day, and the four other
patients received pegylated IFN at 1.5 mg/kg weekly with the
same dose of ribavirin. The mean duration of anti-HCV
therapy was 18710 months (range 6–24 months). The mean
duration of follow-up after completing anti-HCV treatment
was 16.7717.7 months (range 6–30 months). A sustained
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virological response was observed in 67% of patients.
Pegylated IFN was given in three virological responders and
one non-responder. After anti-HCV treatment, proteinuria
and cryoglobulins levels decreased. In addition, serum
albumin level increased significantly in virological responders
compared to non-responders who were receiving the
combination therapy as well as the control patients who
were receiving any anti-viral treatment. In contrast, serum
creatinine level remained stable in all three groups. Our data
suggest that the anti-viral therapy should be given for a long
period. We recommend to treat the patients for at least 48
weeks, and to continue the anti-viral therapy even in the
absence of a decrease in HCV RNA concentration of 2 log at
week 12. After HCV RNA clearance, cryoglobulinemia
persists for a long period.
Despite the absence of a complete and sustained
virological response, ribavirin monotherapy has been shown
to have a beneficial effect on HCV-related glomerulopathy in
immunocompetent patients,16 as well as in renal-17 and liver-
transplant patients.18 However, in patients with impaired
renal function, ribavirin should be given with caution
because its clearance is correlated with creatinine clearance.19
The accumulation of ribavirin induces hemolytic anemia.
Severe chronic hemolysis is responsible for iron overload,
liver iron deposition and an acceleration in liver fibrosis
progression.20
Immunosuppressive therapy
In the past, patients with mixed cryoglobulinemia, with or
without renal involvement, were treated by plasma exchange
to remove circulating cryoglobulins from the plasma and,
consequently, to diminish the deposition of immune
complexes in the kidney.9 Cyclophosphamide was also used
to improve renal disease by suppressing B-lymphocyte
stimulation and cryoglobulins production.9 Steroid pulses
were administrated to treat glomerular infiltration abnorm-
alities.9 Low doses of oral steroids were also given in some
patients.9 Previous uncontrolled studies that included small
number of patients treated with these therapies showed that
this regime often controlled the acute phase of the disease,
but was often poorly tolerated. The flare-up of HCV RNA
concentration observed during immunosuppressive therapy
may be harmful on HCV-related liver disease. A prospective,
multicenter, randomized, controlled trial of treatment for
HCV-associated glomerulonephritis with steroids and cyclo-
phosphamide, which is followed or not with a-IFN, is
ongoing in Italy. Its aim is to evaluate the consequences of
increasing HCV replication by immunosuppressive therapy
on the efficacy of a-IFN therapy.2
Recently, rituximab, a human–mouse chimeric monoclo-
nal antibody that reacts with the CD20 antigen, thus directly
and selectively targeting the B cells, has proved effective and
very well tolerated in patients with B-cell non-Hodgkin’s
lymphomas. Hence, it was used to treat mixed cryoglobuli-
nemia and HCV-related cryoglobulinemic MPGN. Zaja
et al.21 treated patients with rituximab at four weekly doses
of 375 mg/m2. Two of these patients, with HCV-related
cryoglobulinemic MPGN, were unresponsive to conventional
treatments, including a-IFN, plasmapheresis, steroids, and
either cyclophosphamide or 2-chlorodeoxyadenosyne. A
rapid response, and the disappearance of proteinuria and
inactive urinary sediment, was observed in one patient who
had a recent onset of nephritis. No improvement was noticed
in the second patient when rituximab was interrupted
after two infusions due to a thrombosis of the retinal artery.
In the patient who completed rituximab therapy, HCV RNA
concentration showed minimal fluctuations.21 Later, Rocca-
tello et al.22 treated six patients who had HCV-related
cryoglobulinemic glomerulonephritis with rituximab. One
patient received the standard four weekly doses, and the
five other patients were treated by the standard protocol, plus
two additional infusions at 1 and 2 months later. Proteinuria
was decreased in all patients. Serum creatinine level decreased
in two patients, increased in one patient and remained
stable in the three other patients. Interestingly, HCV viral
load decreased or remained stable in all patients. Very
recently, a renal-transplant patient who was experiencing
a de novo HCV-related type III cryoglobulinemic MPGN
was treated with rituximab therapy: he had a clearance of
cryoglobulinemia, a decrease in proteinuria and no change
in serum creatinine or HCV RNA.23 We have also found that
rituximab is efficient in treating de novo cryoglobulinemic
MPGN in HCV-positive or -negative renal-transplant
patients, but is associated with a high rate of infectious
complications, which might be related to the impairment of
T- and B-cell functions that these patients experience.23
Further controlled randomized studies are required to define
the exact indications of rituximab, the dose of rituximab
required, as well as its long-term effect on HCV liver disease.
After controlling the nephrotic syndrome by either
plasmapheresis or rituximab, a combined anti-viral therapy
associating standard or pegylated IFN with or without
ribavirin should be set up. The efficacy of the anti-viral
therapy after a deep immunosuppression induced by
rituximab is not established. Prospective studies using
rituximab followed by anti-viral therapy are required.
IN SUMMARY
Cryoglobulinemic membranoproliferative glomeronephritis
is the most frequent HCV-related renal injury (Table 1). All
patients should be treated with angiotensin-converting
enzyme inhibitor in association or not with angiotensin
receptor antagonist, as well as with anti-HCV therapy. The
latter relies on a combined anti-viral therapy of standard or
pegylated IFN and ribavirin for at least 48 weeks. Ribavirin
doses should be adapted according to creatinine clearance in
order to avoid its main side effect, that is, hemolytic anemia.
Combined anti-viral and immunosuppressive therapies may
be the treatment of choice for patients with severe renal
disease, that is, nephrotic syndrome and/or progressive renal
failure, or diseases that are refractory to anti-HCV therapy
alone. During the acute phase, plasmapheresis and steroid
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pulses might be used to, respectively, remove circulating
cryoglobulins from the plasma and to treat the glomerular
infiltration abnormalities. Even in the absence of controlled
randomized studies, anti-CD20 monoclonal antibodies
should be preferred to cyclophosphamide. Rituximab was
found to be at least as efficient as cyclophosphamide in
blocking cryoglobulins production. It is also better tolerated
and seems, in contrast to cyclophosphamide, not to enhance
HCV replication. Future prospective, controlled and random-
ized studies are still required to establish evidence-based
guidelines to treat HCV-related glomerulopathies.
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Table 1 | Treatment of HCV-related glomerulonephritis
Patients with moderate proteinuria and non-rapid but progressive renal
failure:
Symptomatic treatment
Anti-HCV therapy for at least 12 months
Standard a-IFN 3 MU three times/week or pegylated a-IFN 1.5 mg/kg/
week
Ribavirin: dose adapted to the creatinine clearance or to a trough
plasma concentration of 10–15 mmol/l with or without
erythropoı¨etin support
Patients with nephrotic-range proteinuria and/or progressive renal failure:
Symptomatic therapy: furosemide, ACEI alone or combined with an
ARA
Plasma exchange: 3 l of plasma three times/week for 2 or 3 weeks
Rituximab: 375 mg/m2/week for 4 weeksa or cyclophosphamide:
2 mg/kg/day for 2–4 months
Methylprednisolone pulses: 0.5–1 g/day for three consecutive days
Anti-HCV therapy (see above)
aAdditional infusions of rituximab might be given in cases of early relapse after
conventional therapy.
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